These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 1283856)
1. Hodgkin's disease: summary of twenty years' experience. Mazza P; Bocchia M; Zinzani PL; Fiacchini M; Gherlinzoni F; Bandini G; Bendandi M; Frezza GP; Neri S; Barbieri E Haematologica; 1992; 77(6):487-93. PubMed ID: 1283856 [TBL] [Abstract][Full Text] [Related]
2. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center]. Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222 [TBL] [Abstract][Full Text] [Related]
3. Hodgkin's disease. A historical perspective. Avilés A; Díaz-Maqueo JC; Torras V; Ayala JR; Cortés HD Arch Invest Med (Mex); 1991; 22(1):27-33. PubMed ID: 1726450 [TBL] [Abstract][Full Text] [Related]
4. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy). De Lena M; Ditonno P; Lorusso V; Timurian A; Pellecchia A; Brandi M; Berardi F; Marzullo F Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457 [TBL] [Abstract][Full Text] [Related]
5. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma]. Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946 [TBL] [Abstract][Full Text] [Related]
6. Analysis of the risk of solid tumor following Hodgkin's disease. Maurizi Enrici R; Anselmo AP; Osti MF; Santoro M; Tombolini V; Mandelli F; Biagini C Haematologica; 1997; 82(1):57-63. PubMed ID: 9107084 [TBL] [Abstract][Full Text] [Related]
7. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578 [TBL] [Abstract][Full Text] [Related]
8. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study. Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131 [TBL] [Abstract][Full Text] [Related]
9. Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia. Zinzani PL; Fiacchini M; Mazza P; Gherlinzoni F; Bocchia M; Tura S Haematologica; 1991; 76(4):305-10. PubMed ID: 1724437 [TBL] [Abstract][Full Text] [Related]
11. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors. Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496 [TBL] [Abstract][Full Text] [Related]
12. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute. Bonadonna G; Viviani S; Bonfante V; Gianni AM; Valagussa P Eur J Cancer; 2005 May; 41(7):998-1006. PubMed ID: 15862748 [TBL] [Abstract][Full Text] [Related]
13. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD. Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040 [TBL] [Abstract][Full Text] [Related]
14. [Second neoplasms as a late complication of the treatment of Hodgkin's disease]. Morales MD; González FA; Villegas A; del Potro E; Díaz Mediavilla J; Martínez R; Alvarez A; Colomé JA Sangre (Barc); 1992 Dec; 37(6):429-33. PubMed ID: 1293793 [TBL] [Abstract][Full Text] [Related]
15. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727 [TBL] [Abstract][Full Text] [Related]
16. Hodgkin's disease and the risk of acute leukemia in successfully treated patients. Valagussa P; Bonadonna G Haematologica; 1998 Sep; 83(9):769-70. PubMed ID: 9825571 [No Abstract] [Full Text] [Related]
17. [Cured from Hodgkin's disease]. Brice P Bull Cancer; 2002; 89(7-8):666-70. PubMed ID: 12206979 [TBL] [Abstract][Full Text] [Related]
18. Hodgkin's disease: controversies and challenges for the future. Tura S; Canellos G; Goldstone A; Longo D; McMillan A; Urba W; Zinzani PL Haematologica; 1991; 76(4):263-79. PubMed ID: 1724436 [No Abstract] [Full Text] [Related]
19. Pediatric Hodgkin's disease. Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795 [TBL] [Abstract][Full Text] [Related]
20. Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results. Bonadonna G; Santoro A; Bonfante V; Valagussa P Cancer Treat Rep; 1982 Apr; 66(4):881-7. PubMed ID: 6176323 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]